share_log

NeuroSense Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Apr 4 16:42
Summary by Moomoo AI
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on April 4, 2024. This amendment updates the registration statement under the Securities Act of 1933 for the issuance of up to 1,755,000 ordinary shares underlying previously issued warrants. The company, based in Israel, specializes in developing treatments for neurodegenerative diseases and has been granted orphan drug designation for its lead therapeutic candidate, PrimeC, by both the FDA and EMA. The amendment includes financial statements for the year ended December 31, 2023, and details the company's ability to indemnify officers, the appointment of Cogency Global Inc. as the agent for service of process in the U.S., and the company's amended and restated articles of association. The ordinary shares and warrants trade on the Nasdaq under the symbols 'NRSN' and 'NRSNW' respectively.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on April 4, 2024. This amendment updates the registration statement under the Securities Act of 1933 for the issuance of up to 1,755,000 ordinary shares underlying previously issued warrants. The company, based in Israel, specializes in developing treatments for neurodegenerative diseases and has been granted orphan drug designation for its lead therapeutic candidate, PrimeC, by both the FDA and EMA. The amendment includes financial statements for the year ended December 31, 2023, and details the company's ability to indemnify officers, the appointment of Cogency Global Inc. as the agent for service of process in the U.S., and the company's amended and restated articles of association. The ordinary shares and warrants trade on the Nasdaq under the symbols 'NRSN' and 'NRSNW' respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more